AZ, Abbott dump heart drug

Following up on the FDA's decision to spurn the experimental heart drug Certriad back in March, Abbott and AstraZeneca announced that they were dumping the program. Regulators had asked for more data on the drug but the pharma companies said that the delay would kill the drug's market potential. This is AZ's third setback in the past week. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.